GLP-1 Receptor Agonists Show Complex, Evolving Role in Alopecia Areata

The emerging and sometimes contradictory relationship between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and hair disorders, particularly alopecia areata, was the subject of a talk by Natasha Atanaskova Mesinkovska, MD, PhD, at the 2026 American Academy of Dermatology (AAD) Annual Meeting.

“Everything that happens with hair has inflammation,” Dr. Mesinkovska said, emphasizing the central role of inflammatory pathways in hair biology. 

She highlighted the growing recognition of adipose tissue as an active endocrine organ rather than a passive storage site.

“Fat is not a blob; it is actually very active. … It makes hormones and a lot of inflammatory cytokines,” she explained. 

This metabolic inflammation, she noted, can negatively affect hair growth and even mimic aging pathways through cytokine signaling and COX-mediated inflammation. Obesity-related inflammation has been replicated in experimental models and is increasingly understood as a contributor to hair disorders.

While GLP-1 RAs are widely used for weight management, Dr. Mesinkovska emphasized their broader biologic effects.

“It is not just something that shuts your mouth,” she said. “It also is very, very anti-inflammatory.” 

She described GLP-1 as a short-lived endogenous peptide that has been modified into longer-acting receptor agonists to improve metabolic regulation. Beyond glycemic control, these agents may influence systemic inflammation, insulin signaling, and microvascular function—all of which have implications for hair follicle health.

Despite potential anti-inflammatory benefits, GLP-1 RA therapy is frequently associated with hair shedding in clinical practice.

“As they lose weight, their hair will fall out. This is real,” Dr. Mesinkovska said. 

She pointed to data suggesting that rapid weight loss, particularly in women, is strongly associated with telogen effluvium–like shedding.

“The faster you lose your weight … the more hair we lose,” she noted. 

At the same time, preclinical data suggest a potential pro-growth effect at the follicular level.

“When you inject GLP … they grow tons of hair,” she said, citing experimental findings demonstrating activation of MAP kinase pathways within the follicle. 

Clinical data remain limited but intriguing. Dr. Mesinkovska highlighted analyses suggesting that patients with alopecia areata may actually experience improvement while on GLP-1 RA therapy.

“What they showed is what we all think: it is beyond the weight loss, and it is the anti-inflammatory effect,” she said. 

She also shared anecdotal clinical experience, noting reduced reliance on systemic therapies in some patients. These observations align with broader evidence that GLP-1 RAs can reduce systemic inflammatory markers such as ESR and CRP, sometimes rapidly and independently of significant weight loss.

Dr. Mesinkovska emphasized the need for clinician awareness of both risks and opportunities. Hair loss associated with GLP-1 RA therapy is likely multifactorial, driven in part by nutritional shifts and rapid metabolic change. At the same time, the anti-inflammatory properties of these agents may offer therapeutic benefit in select patients with inflammatory hair disorders.

“This is not just about weight loss,” she said. “We are repairing tissue … working on the cells at a deeper level.” 

She advised a cautious, individualized approach, particularly in patients with alopecia areata or other inflammatory conditions.

“There’s no rush,” she said. “Low dose … and we’re going to learn more.”